Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology.

INTRODUCTION: We investigated if "thermobalancing" therapy (TT), using Dr Allen's therapeutic device (DATD) in men with benign prostatic hyperplasia (BPH), can aid in understanding the etiology and pathophysiology of BPH. METHODS: We compared urinary and other parameters of BPH patients who received TT over 6 months (treatment group) with those of healthy volunteers who had not received the treatment (control group). Dynamics of symptoms and indicators in each group were evaluated in comparison with their data at the beginning and end of the study. Parameters were the International Prostate Symptom Score (IPSS) for urinary symptoms and quality of life (QoL), ultrasound measurement of prostate volume (PV) and uroflowmetry (maximum flow rate, Qmax). TT effectiveness was examined in 124 men with BPH and PV <60 mL. We also investigated the data of five patients with BPH and PV >60 mL. RESULTS: TT decreased urinary symptoms and PV, increased Qmax and improved QoL in men with BPH, PV <60 mL, and in men with BPH, PV >60 mL. CONCLUSIONS: The present study demonstrated that TT is effective for BPH, suggesting that blood circulation plays a crucial role in its cause. The continuous heat exposure that does not exceed the normal body temperature terminates the trigger of BPH development, "micro-focus" of hypothermia, and the following spontaneous expansion of capillaries. TT could be considered to be a useful tool in BPH treatment.

Efficacy of thermobalancing therapy for chronic prostatitis/chronic pelvic pain syndrome, confirmed by clinical study, may suggest etiology and pathophysiology of this disease.

INTRODUCTION: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) type-III is a common disorder characterized by pelvic pain and lower urinary tract symptoms in the absence of active infection. The aim of this clinical study is to evaluate the results of thermobalancing therapy (TT) and to discus the possible etiology and pathophysiology of CP/CPPS. METHODS: 45 patients with CP/CPPS used TT by applying therapeutic device, namely Dr Allen's therapeutic device (DATD), for six months as monotherapy. The control group comprised 45 men who did not receive TT. The National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores, prostatic volume (PV) by ultrasound measurement, and uroflowmetry (Qmax) were compared between both groups. RESULTS: Compared to controls, the treatment group showed significant improvements from baseline to endpoint in pain score, (p<0.001), quality of life index (QoL) (p<0.001), PV (p<0.001), and Qmax (p<0.001). CONCLUSIONS: The clinical study has confirmed that six-month TT with DATD reduces CP/CPPS symptoms dramatically. DATD uses emitted body heat as a source of energy to the projection of prostate for a pronged period of time, which removes microfocus of hypothermia in the prostate tissue gradually, improving blood circulation and consequently relieving the problem. Thus, the etiology and pathophysiology of CP/CPPS may be viewed as a chain of events in which initial inflammation in the prostate tissue leads to spontaneous capillary expansion, increasing pressure in the gland that sets up secondary, continuous-trigger, microfocus of hypothermia. It makes the problem chronic. TT, by eliminating this focus of hypothermia and pressure in the prostate gland, provides pelvic pain relief and improves QoL of men with CP/CPPS. The effectiveness of therapy allows us to recommend DATD for patients with CP/CPPS.

Positive Response to Thermobalancing Therapy Enabled by Therapeutic Device in Men with Non-Malignant Prostate Diseases: BPH and Chronic Prostatitis.

BACKGROUND: The most common types of non-malignant prostate diseases are benign prostatic hyperplasia (BPH) and chronic prostatitis (CP). The aim of this study was to find out whether thermobalancing therapy with a physiotherapeutic device is effective for BPH and CP. METHODS: During a 2.5-year period, 124 men with BPH over the age of 55 were investigated. Clinical parameters were tested twice: via the International Prostate Symptom Score (IPSS) and via ultrasound measurement of prostate volume (PV) and uroflowmetry maximum flow rate (Qmax), before and after six months of therapy. In 45 men with CP under the age of 55, the dynamics of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) were studied. RESULTS: The results of the investigated index tests in men with BPH confirmed a decrease in IPSS (p < 0.001), a reduction in PV (p < 0.001), an increase in Qmax (p < 0.001), and an improvement of quality of life (QoL) (p < 0.001). NIH-CPSI scores in men with CP indicated positive dynamics. CONCLUSIONS: The observed positive changes in IPSS, PV, and Qmax in men with BPH and the improvement in NIH-CPSI-QoL in patients with CP after using a physiotherapeutic device for six months as mono-therapy, support the view that thermobalancing therapy with the device can be recommended for these patients. Furthermore, the therapeutic device is free of side effects.

Benign Prostatic Hyperplasia Treatment with New Physiotherapeutic Device.

PURPOSE: Thermobalancing therapy, provided by Therapeutic Device, which contains a natural thermoelement, and is applied topically in the projection ofthe prostate,was aimed to improve blood circulation in the affected organ. We evaluated the effectiveness of new Therapeutic Device for the treatment of patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: We performed a clinical non-randomized controlled trial before and after 6-month treatment. Therapeutic Device was administered to 124 patients with BPH as mono-therapy. The dynamic of the patients' condition was assessed by the International Prostate Symptom Score (IPSS), ultrasound measurement of prostate volume (PV) and uroflowmetry. The control-group comprised 124 men who did not receive any treatment. The IPSS score, maximum flow rate (Qmax), and PV were compared between the groups. RESULTS: Baseline evaluation (pre-treatment) for both groups were comparable to each other with no clinically significant difference regarding age, IPSS score, Qmax and PV volume. Overall, thermobalancing therapy resulted in significant improvements from baseline to endpoint in IPSS (P = .001), IPSS storage and voiding subscores (both P = .001), and IPSS quality of life index (QoL) (P = .001) compared with control group. Moreover, comparison of parameters after 6 months treatment showed that thermobalancing therapy also improved the Qmax (P = .001), and PV (P = .001). CONCLUSION: Two years clinical trial demonstrated that thermobalancing therapy administered for 6 months provides a marked improvement in patients presenting with symptomatic BPH not only on lower urinary tract symptoms (LUTS) but also in QoL and Qmax. Thus urologists should be aware about thermobalancing therapy as a non-invasive physiotherapeutic treatment option for treatment of BPH.